



*Inclusion criteria: Any paper was removed from the analysis if it was not written in English or Spanish (n=20), was a non-human study (n=5), was a paediatric study (n=52), was not a case-control study (n=36), did not have a renal disease phenotype (n=90), did not include data for ACE (n=13) or had a pharmaceutical drug focus (n=9)

Supplementary Figure S1a: ACE Study Flow Diagram




*Inclusion criteria: Any paper was removed from the analysis if it was not written in English or Spanish (n=55), was a non-human study (n=119), was a paediatric study (n=149), was not a case-control study (n=53), did not have a renal disease phenotype (n=693), did not include data for ACE2 (n=435) or had a pharmaceutical drug focus (n=44)

Supplementary Figure S1b: ACE2 Study Flow Diagram




Supplementary Figure S1c: AGT Study Flow Diagram




*Inclusion criteria: Any paper was removed from the analysis if it was not written in English or Spanish (n=8), was a non-human study (n=13), was a paediatric study (n=21), was not a case-control study (n=14), did not have a renal disease phenotype (n=25), did not include data for *AGTR1* (n=3), was a gene expression based study (n=1) or had a pharmaceutical drug focus (n=9)

Supplementary Figure S1d: AGTR1 Study Flow Diagram




*Inclusion criteria: Any paper was removed from the analysis if it was not written in English or Spanish (n=1), was a non-human study (n=2), was a paediatric study (n=6), was not a case-control study (n=4), did not have a renal disease phenotype (n=5) or did not include data for *AGTR2* (n=6)


Supplementary Figure S1e: AGTR2 Study Flow Diagram




Supplementary Figure S1f: REN Study Flow Diagram




Supplementary Figure S2a: Forest plot - ACE I/D investigation, individuals with type 1 diabetic nephropathy compared to individuals with type 1 diabetes mellitus in a European population (ACE insertion compared to deletion).




Supplementary Figure S2b: Forest plot - ACE I/D investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a European population (ACE insertion compared to deletion).




Supplementary Figure S2c: Forest plot - ACE I/D investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a Middle Eastern population (ACE insertion compared to deletion).




Supplementary Figure S2d: Forest plot - ACE I/D investigation, individuals with chronic kidney disease compared to healthy controls in a South Asian population (ACE insertion compared to deletion).




Supplementary Figure S2e: Forest plot - ACE I/D investigation, individuals with end-stage renal disease compared to healthy controls in a European population (ACE insertion compared to deletion).




Supplementary Figure S2f: Forest plot - ACE I/D investigation, individuals with end-stage renal disease compared to healthy controls in a Middle Eastern population (ACE insertion compared to deletion).




Supplementary Figure S2g: Forest plot - *ACE* I/D investigation, individuals with end-stage renal disease linked to type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in an East Asian population (*ACE* insertion compared to deletion).




Supplementary Figure S2h: Forest plot - *ACE* I/D investigation, individuals with end-stage renal disease linked to type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S2i: Forest plot - *ACE* I/D investigation, individuals with IgA nephropathy compared to healthy controls in an East Asian population (*ACE* insertion compared to deletion).




Supplementary Figure S2j: Forest plot - *ACE* I/D investigation, individuals with IgA nephropathy compared to healthy controls in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S2k: Forest plot - *ACE* I/D investigation, individuals with primary glomerulonephritis compared to healthy controls in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S2l: Forest plot - *ACE* I/D investigation, individuals who have had renal transplants compared to healthy controls in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S3a: Funnel plot - *ACE* I/D investigation, individuals with type 1 diabetic nephropathy compared to individuals with type 1 diabetes mellitus in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S3b: Funnel plot - *ACE* I/D investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S3c: Funnel plot - *ACE* I/D investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a Middle Eastern population (*ACE* insertion compared to deletion).




Supplementary Figure S3d: Funnel plot - *ACE* I/D investigation, individuals with chronic kidney disease compared to healthy controls in a South Asian population (*ACE* insertion compared to deletion).




Supplementary Figure S3e: Funnel plot - *ACE* I/D investigation, individuals with end-stage renal disease compared to healthy controls in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S3f: Funnel plot - *ACE* I/D investigation, individuals with end-stage renal disease compared to healthy controls in a Middle Eastern population (*ACE* insertion compared to deletion).




Supplementary Figure S3g: Funnel plot - *ACE* I/D investigation, individuals with end-stage renal disease linked to type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in an East Asian population (*ACE* insertion compared to deletion).




Supplementary Figure S3h: Funnel plot - *ACE* I/D investigation, individuals with end-stage renal disease linked to type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S3i: Funnel plot - *ACE* I/D investigation, individuals with IgA nephropathy compared to healthy controls in an East Asian population (*ACE* insertion compared to deletion).




Supplementary Figure S3j: Funnel plot - *ACE* I/D investigation, individuals with IgA nephropathy compared to healthy controls in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S3k: Funnel plot - *ACE* I/D investigation, individuals with primary glomerulonephritis compared to healthy controls in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S3l: Funnel plot - *ACE* I/D investigation, individuals who have had renal transplants compared to healthy controls in a European population (*ACE* insertion compared to deletion).




Supplementary Figure S4a: Forest plot - *AGT* rs699 investigation, individuals with type 1 diabetic nephropathy compared to individuals with type 1 diabetes mellitus in a European population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S4b: Forest plot - *AGT* rs699 investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in an East Asian population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S4c: Forest plot - *AGT* rs699 investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a European population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S4d: Forest plot - AGT rs699 investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a Middle Eastern population (AGT rs699 T allele compared to C allele).




Supplementary Figure S4e: Forest plot - AGT rs699 investigation, individuals with end-stage renal disease compared to healthy controls in an East Asian population (AGT rs699 T allele compared to C allele).




Supplementary Figure S4f: Forest plot - AGT rs699 investigation, individuals with IgA nephropathy compared to healthy controls in an East Asian population (AGT rs699 T allele compared to C allele).




Supplementary Figure S5a: Funnel plot - *AGT* rs699 investigation, individuals with type 1 diabetic nephropathy compared to individuals with type 1 diabetes mellitus in a European population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S5b: Funnel plot - *AGT* rs699 investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in an East Asian population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S5c: Funnel plot - *AGT* rs699 investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a European population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S5d: Funnel plot - *AGT* rs699 investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in a Middle Eastern population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S5e: Funnel plot - *AGT* rs699 investigation, individuals with end-stage renal disease compared to healthy controls in an East Asian population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S5f: Funnel plot - *AGT* rs699 investigation, individuals with IgA nephropathy compared to healthy controls in an East Asian population (*AGT* rs699 T allele compared to C allele).




Supplementary Figure S6a: Forest plot - *AGTR1* rs5186 investigation, individuals with type 1 diabetic nephropathy compared to individuals with type 1 diabetes mellitus in a European population (*AGTR1* rs5186 A allele compared to C allele).




Supplementary Figure S6b: Forest plot - *AGTR1* rs5186 investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in an East Asian population (*AGTR1* rs5186 A allele compared to C allele).




Supplementary Figure S6c: Forest plot - *AGTR1* rs5186 investigation, individuals with IgA nephropathy compared to healthy controls in an East Asian population (*AGTR1* rs5186 A allele compared to C allele).



Supplementary Figure S7a: Funnel plot - *AGTR1* rs5186 investigation, individuals with type 1 diabetic nephropathy compared to individuals with type 1 diabetes mellitus in a European population (*AGTR1* rs5186 A allele compared to C allele).



Supplementary Figure S7b: Funnel plot - *AGTR1* rs5186 investigation, individuals with type 2 diabetic nephropathy compared to individuals with type 2 diabetes mellitus in an East Asian population (*AGTR1* rs5186 A allele compared to C allele).



Supplementary Figure S7c: Funnel plot - *AGTR1* rs5186 investigation, individuals with IgA nephropathy compared to healthy controls in an East Asian population (*AGTR1* rs5186 A allele compared to C allele).